Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,465 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Solid Tumors, Adult Clear all

Conditions: Neoplasms
Interventions: AZD 2281, Cisplatin, Gemcitabine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoma, Ewing, Rhabdomyosarcoma
Interventions: PEN-866, Vincristine, Temozolomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 39 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions: TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more

Conditions: Cancer
Interventions: cyclophosphamide, Cryoablation; Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Interventions: ABBV-637, Docetaxel, Osimertinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • Huntersville, North Carolina + 3 more

Conditions: Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
Interventions: Neratinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 5 more

Conditions: Solid Tumors
Interventions: GS-9911, Zimberelimab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: New Haven, Connecticut • Nashville, Tennessee • San Antonio, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: GPX-100; Drug
Lead sponsor: Gem Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Jacksonville, Florida • Salt Lake City, Utah

Conditions: Solid Tumor, Adult
Interventions: Yoga; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: dexamethasone, dronabinol, palonosetron hydrochloride, placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 4
States / cities: Springfield, Missouri • Greenville, South Carolina • Houston, Texas + 1 more

Conditions: Solid Tumor, Adult
Interventions: Isunakinra, PD-(L)1 Inhibitor; Biological
Lead sponsor: Buzzard Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Retinoblastoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: filgrastim, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 2
States / cities: New York, New York

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: benzoylphenylurea; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: intensity-modulated radiation therapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 60
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 51 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PR610; Drug
Lead sponsor: Proacta, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 1 more

Conditions: Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions: KIN-3248; Drug
Lead sponsor: Kinnate Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Jacksonville, Florida + 9 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: biologic sample preservation procedure, medical chart review, questionnaire administration; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Solid Tumors, Adult, Multiple Myeloma, Lymphoma
Interventions: VP301; Drug
Lead sponsor: Virtuoso BINco, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: veliparib, capecitabine, oxaliplatin, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lymphedema, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: placebo for study drug, (RS)2-(3-benzoylphenyl)-propionic acid, laboratory biomarker analysis; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Sorafenib; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Solid Tumor, Adult, Solid Tumor Cancer
Interventions: DF6215, pembrolizumab, KEYTRUDA®; Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Diego, California + 5 more

Conditions: Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
Interventions: Decoy20, Tislelizumab; Drug
Lead sponsor: Indaptus Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more

Conditions: Advanced Solid Tumor, Adult
Interventions: RP-3500 (camonsertib); Drug
Lead sponsor: Repare Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 9 more

Search by objective public record fields.

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

GPX-100 in Treating Patients With Solid Tumors

Yoga for Solid Tumor

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

Benzoylphenylurea in Treating Patients With Advanced Solid Tumors

Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema

Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

Study of DF6215 in Patients With Advanced Solid Tumors

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors